Overview
Aortic valve replacement (AVR) through minimally invasive surgery (MIS) may provide benefits to patients over conventional full sternotomy (FS) . A novel class of bioprosthetic rapid deployment valves for aortic valve replacement (RDAVR)* have been developed to help overcome the technical complexity associated with performing MIAVR.
The CADENCE-MIS trial was a prospective, randomised, multicentre trial that compared the outcomes of MIS-RDAVR with FS for AVR using a conventional stented aortic bioprosthesis.
Between May 2012 and February 2013, 100 patients with aortic stenosis were enrolled, and surgeries were performed at 5 centres in Germany. 
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Conclusion
Haemodynamic outcomes such as EOA and transvalvular gradients in MIS-RDAVR* patients, were significantly better when compared to conventional valve patients after 1 year.
MIS-RDAVR* was also associated with statistically significant reduction in aortic cross-clamp times compared with FS-AVR. 
